AstraZeneca’s Brilinta reduces the rate of stroke and death in patients with acute ischaemic stroke or transient ischaemic attack
pharmafile | July 16, 2020 | News story | Business Services | AZ, AstraZeneca, drug trials
AstraZeneca’s Phase 3 THALES trial showed that Brilinta (ticagrelor) significantly reduced the rate of death or stroke in patients with acute ischaemic stroke or transient ischaemic attack (TIA).
The results were published in The New England Journal of Medicine, and patients took 90mg of Brilinta twice daily with aspirin for 30 days. This reduced the rate of the primary endpoint of stroke and death by 17% compared to aspirin alone in TIA patients. This was a statistically significant and a clinically meaningful reduction. Brilinta combined with aspiring also significantly reduced the rate of schaemic stroke by 21%, compared to aspirin alone up to day 30.
Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca, said: “Patients who had an acute ischaemic stroke or transient ischemic attack may experience a subsequent, potentially avoidable stroke. Results from the Phase III THALES trial confirm that aspirin plus Brilinta has the potential to be a new effective treatment option for these high-risk patients and we look forward to continuing discussions with regulatory authorities.”
The FDA accepted a New Drug Application and granted a Priority Review for Brilinta for TIA based on this Phase 3 trial. It is already approved in more than 110 countries for the prevention of atherothrombotic events in adult patients with acute coronary syndrome (ACS) and in more than 70 countries for the secondary prevention of cardiovascular events among high-risk patients who have experienced a heart attack.
Conor Kavanagh
Related Content
NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …
NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …
Purpose and people: the enduring power of brand and the evolution of employer identity
Two decades ago, terms like purpose and people were rarely at the forefront of branding …
